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THE USE OF EBV-SPECIFIC CYTOTOXIC T LYMPHOCYTES AS ADJU- 
VANT THERAPY POST STEM CELL TRANSPLANT FOR RELAPSED EBV- 
POSITIVE HODGKIN DISEASE 
Bollm'd, C.M.; Straathofi K.C.; Ha/s, H.; Lacaesta, RI; GJ-esik, M. l,i; 
Carrum, G.; Brenner', M.I<.; Rooney, C.M.; Heslop, H.E. Pediat~'ic 
He,~atology/Oneologv, Baylor College of MediciJ, e, Ho,tston, TX. 
Adoptive transfer of EBV specific cytotoxic T cells(CTL) has 
proved effective in preventing and treating immunogenic EBV 
lymphomas expressing type 3 EBV latency arising after hemopoi- 
etic stem cell transplantation(SCT). he tumor cells in around 
40% of cases of Hodgkin disease(HD) also contain the EBV 
genome although amore restricted array of EBV proteins includ- 
ing the subdominant EBV antigens LMP1 and LMP2 are 
expressed. We have evaluated the use of polyclonal EBV-CTL in 
patients with EBV+ HD with minimal residual disease post SCT. 
23 patients were referred to receive CTL post autologous SCT 
and 6 (26%) had EBV+ minors. 5 of these patients were treated 
with autologous CTL as adjuvant therapy post autologous SCT. 
Three received CTL at 2xI07/m -' and 2 received a CTL dose of 
1.2xl0S/m 2.An additional patient with EBV+ HD received an 
allogeneic SCT fi'om an unrelated onor and received one dose of 
2 x 10Vm-' donor-derived CTL. No immediate toxicity was 
observed post CTL. In tbe patient who received allogeneic CTL, 
the donor-derived CTL line showed 0.03% and 0.62% positivity 
for the A2 LMP2 tetramers and 2.49% for the LMP1 tetramer. 
No increase in the LMP2 tetramer population was seen post allo- 
geneic CTL but a 4-fold increase in the LMP1 tetramer popula- 
tion was demonstrated at 3 months. In the autologous CTL lines 
generated fi'onr 6 evaluble patients, an average of 1.61% (0.02- 
7.66%) of CD8 T cells were +ve for LMP2 which was similar to 
the frequency seen in CTL lines generated from normal donors. 
Using ELISPOT assay for yIFN secretion we saw a 1.5 to 2-fold 
increase in CTLp by 6 weeks in 3 patients. One patient had reso- 
lution of an abnormal gallium scan post CTL associated with 
reduced EBV DNA levels and a 4-fold increase in LMP2-specific 
CTL as detected by ELISPOT assay. Of the 5 patients who have 
received CTL after autologons SCT, 4 are well 12-30 mths post 
CTL. One patient died 3 mths post CTL with progressive disease. 
The patient who received allogeneic CTL remains welI 23 mths 
post SCT. In conclusion, EBV-specific CTL as adjuvant therapy 
post SCT appears afe at the lowest dose levels and anti-tumor 
effects have been observed. LMP2 or LMPI CTL are increased in 
the peripheral blood post CTL infusion and strategies to increase 
their frequency may result in a more specific cytotoxic response 
against EBV+ Hodgkin tumors. 
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REDUCED EARLY TRANSPLANT-RELATED MORTALITY FOLLOWING 
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) WITH FLUDARA- 
BINE-BASED, REDUCED-INTENSITY CONDITIONING FROM MATCHED 
RELATED AND UNRELATED DONORS IN ADVANCED HODGKIN'S DIS- 
EASE (HD) 
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Allogeneic SCT following a FDDP-based conditioning regimen 
was carried out in 25 patients with very advanced HD who failed 
multiple conventional treatments (median chemotherapy regi- 
mens: 5; range 2-9), radiation therapy (17/25) and a prior autolo- 
gous SCT (18/25). The median age was 30 years (18 56). Disease 
status at SCT was refractory relapse (n=8) and sensitive relapse 
(n=17). The median time to progression after autologous SCT 
was 9 months (2.5-52). The cell source was rhG-CSF-mobilized 
blood stem ceils from an HLA-identical sibling (n=12) or matched 
unrelated onor marrow (MUD; n=13). The conditioning regi- 
men was FDDP-cyclophosphamide)-_+ antithymocyte globulin 
(FC+_ATG) (n=13), and FDDP melphalan (FM140) (n=12). 8/12 
FM patients had a matched unrelated onor. Graft vs-host disease 
(GVHD) prophylaxis was tacrolimus and methotrexate. Myeloid 
recovery was prompt, with an absolute neutrophil count 
(ANC)>500/:L at day 11 (9-24). Median platelet recovery at 
20K/:L was at day i7 (9-50), with 7 patients never dropping below 
20K/:L after SCT, Chimerism and/or cytogenetic studies at day 
30-100 indicate 100% donor-derived engraftment in 12/12 
(100%) evaluable FM patients and in 7/12 (58%) evaluable 
FC_+ATG patients. Day 100 transplant-related mortality (TRT) 
was only 2/25 (8%) overall. It was 0/12 (0%) in sibling SCT recip- 
ients, and was 2/13 (15%) in MUD SCT recipients. Both 
deceased patients were MUD transplant recipients and one had 
been conditioned with FM140. Acute GVHD occurred in 13/23 
(56%) evaluable patients. Chronic GVHD was diagnosed in 11 
patients (extensive in 9). Nine patients have expired (8/9 received 
FC_+ATG), non-relapse mortality is 4/9 (44%) overa]l. Sixteen 
patients (64%) are alive (nine in remission) with a median follow- 
up of 10 months (1-51). Mlogeneic SCT from related and unrelat- 
ed donors with fludarabine-based, less intensive conditioning is
feasible in very high-risk, heavily pretreated HD. It yielded very 
promising results on engraftment, acute GVHD and, in particular, 
early TRT rates. The FM140 regimen is seemingly better suited 
for these patients. 
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A NOVEL STRATEGY FOR GENERATING LMPI SPECIFIC T CELLS UTI- 
LIZING ARTIFICIAL ANTIGEN PRESENTING CELLS 
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E. 1; Sadelain, M.s; O'Reilly, R.J. I 1. M,w, ovkd Sloan-Kettering Ca*~cev 
CenteJ , New York, NIT; 2. University of North Carolina at Chapel Hill, 
Chapel Hill, NC. 
EBV contributes to the etiology of several human malignancies. 
However EBV+ nasopharyngeal carcinoma, EBV associated 
Hodgkins disease and leiomyosarcoma, express only the poorly 
immunogenic EBV antigens EBNAI, LMP 1 and LMP2. To gener- 
ate LMP1 specific CTL reactive against HLA-A0201+ EBV+ 
tumors, we used 3T3 cells genetically modified to express ttLA- 
A0201, beta2-microglobulin, the human co-stimulatory molecules 
BT.I, ICAM-1, LFA-I and the HLA-A0201 binding LMP1 peptide 
(YLLEMLWRL)  as artificial antigen presenting cells (AAPC) to 
stimulate T cells isolated from 9 HLA A0201+normaI donors. 
Control cultures were generated fi'om the same individuals against 
autologous EBV BLCL and against AAPCs expressing an Influenza 
matrix peptide rather than LMPI. LMP1 specific CDS+ T cells 
were quantitated with HLA-A0201-LMPI.1 tetramers; their spe- 
cific cytotoxicity was assessed by a standard 51Cr release assays. 
After 12 days, 8-17% of T ceils sensitized with HLA-A2-LMPI.1 
AAPC were tetramer positive and exhibited strong LMP1 specific 
HLA-A0201 restricted cytotoxicity (32-65%) against autologous 
EBV BLCLs. The specificity of cytoto~c responses against other 
EBV* A0201+ targets was confirmed by analysis of the LMP1 
sequence e~vpressed and was proportional to the level of LMP1 pro- 
tein detected in the target cells by intracellular immunostaining and 
FACS analysis. These T ceils were not reactive against K562, autol- 
ogous or HLA-A2+ PHA blasts, HLA mismatched EBV BLCL or 
mismatched LMPI pulsed targets. They did kill HLA-A0201+ 
EBV negative targets pulsed with LMP1 peptide. Strikingly, these 
CTL were highIy cytotoxic against an HLA-A0201 +EBV- leukemia 
transduced to express LMP1 and an EBV+ HLA-A0201+ nasopha- 
ryngeal carcinoma cell line. Such LMP1 reactive CTLs were not 
detected among T cells sensitized against autologous EBV BLCL. 
Evahiations of these T cells after adoptive transfer in xenografted 
SCID mice are in progress. These results indicate that AAPCs 
expressing LMP1 regularly stimulate the generation of LMP1 spe 
cific CTLs. Such cells could be used for adoptive immunotherapy 
of LMP1 positive malignancies which do not express immunogcnic 
EBV antigens. * this author equalIy contributed 
BB&MT 71 
